Scholarlink

Objectives <p>To evaluate the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) v2018 ancillary features (AFs) and biomarker for hepatocellular carcinomas (HCCs) ≤ 30 mm in Western and Eastern guidelines.</p> Materials and methods <p>This multicenter retrospective study included 1414 patients at risk for HCC who underwent MRI. The odds ratios of LI-RADS features and high alpha-fetoprotein (AFP) levels were assessed. Western and Eastern guidelines’ diagnostic performances were compared via generalized estimating equations.</p> Results <p>A total of 1711 observations ≤ 30 mm were included in the extracellular contrast agent (ECA)-MRI training, internal/external ECA-MRI validation sets (<i>n</i> = 573, 245 and 212), internal EOB-MRI validation set (<i>n</i> = 681). Based on multivariable analysis, using combination of mild-moderate T2 hyperintensity and “either fat in mass or AFP ≥ 200 ng/mL,” named “T2 + F/A” criterion, significantly improved the sensitivities of LR-5 v2018 (80.1–85.0% vs. 73.1–77.1%), EASL v2018 (78.4–84.3% vs. 72.2–75.7%), Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) v2022 (78.4–90.9% vs. 73.4–88.3%), Asian Pacific Association for the Study of the Liver (APASL) v2017 (81.5–94.8% vs. 73.7–90.9%) and Japan Society of Hepatology (JSH) v2021 (81.5–94.5% vs. 73.7–90.6%) for HCCs ≤ 30 mm in the training set and internal and external validation sets (all <i>p</i> &lt; 0.05) without impairing specificity, except for that of Asian Pacific Association for the Study of the Liver (APASL) v2017 in the internal gadoxetic acid (EOB) validation set (75.5% vs. 77.2%, <i>p</i> = 0.044).</p> Conclusion <p>Two LI-RADS AFs (mild-moderate T2 hyperintensity and fat in mass) and AFP ≥ 200 ng/mL are useful for improving the sensitivity of Western and Eastern guidelines for HCCs ≤ 30 mm.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis><i> The sensitivities of Western and Eastern guidelines for hepatocellular carcinoma ≤ 30 mm are still insufficient on extracellular contrast agent-enhanced MRI and gadoxetic acid-enhanced MRI</i>.</p> <p><Emphasis Type="BoldItalic">Findings</Emphasis><i> The use of the integrated “T2 + F/A” diagnostic criterion significantly improved the sensitivity of Western and Eastern guidelines for HCCs ≤ 30 mm on both ECA-MRI and EOB-MRI</i>.</p> <p><Emphasis Type="BoldItalic">Clinical relevance</Emphasis><i> Addressing a critical gap in noninvasive small HCC diagnosis protocols in Western and Eastern guidelines across multiple MRI contrast agents. By enabling more accurate MRI diagnosis of HCCs ≤ 30 mm, our findings could increase patients receiving curative treatments at the early stage, potentially improving outcomes</i>.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The value of LI-RADS ancillary features and biomarker for hepatocellular carcinoma ≤ 30 mm in Western and Eastern guidelines on extracellular agent and gadoxetic acid-enhanced MRI

  • 期刊论文

  • 发表日期：

    2026年2月20日

查看全文
  • Jinhui Zhou,
  • Siyu Ouyang,
  • Haimei Chen,
  • Dingyue Zhang,
  • Yan Wang,
  • Yuanqiang Xiao,
  • Ying Zeng,
  • Zebin Fang,
  • Yufeng Wang,
  • Lichun Chen,
  • Jing Zhang,
  • Tianhui Zhang,
  • Xi Zhong,
  • Qiqi Yang,
  • XinXin Bu,
  • Yang Yang,
  • Jin Wang

摘要

Objectives

To evaluate the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) v2018 ancillary features (AFs) and biomarker for hepatocellular carcinomas (HCCs) ≤ 30 mm in Western and Eastern guidelines.

Materials and methods

This multicenter retrospective study included 1414 patients at risk for HCC who underwent MRI. The odds ratios of LI-RADS features and high alpha-fetoprotein (AFP) levels were assessed. Western and Eastern guidelines’ diagnostic performances were compared via generalized estimating equations.

Results

A total of 1711 observations ≤ 30 mm were included in the extracellular contrast agent (ECA)-MRI training, internal/external ECA-MRI validation sets (n = 573, 245 and 212), internal EOB-MRI validation set (n = 681). Based on multivariable analysis, using combination of mild-moderate T2 hyperintensity and “either fat in mass or AFP ≥ 200 ng/mL,” named “T2 + F/A” criterion, significantly improved the sensitivities of LR-5 v2018 (80.1–85.0% vs. 73.1–77.1%), EASL v2018 (78.4–84.3% vs. 72.2–75.7%), Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) v2022 (78.4–90.9% vs. 73.4–88.3%), Asian Pacific Association for the Study of the Liver (APASL) v2017 (81.5–94.8% vs. 73.7–90.9%) and Japan Society of Hepatology (JSH) v2021 (81.5–94.5% vs. 73.7–90.6%) for HCCs ≤ 30 mm in the training set and internal and external validation sets (all p < 0.05) without impairing specificity, except for that of Asian Pacific Association for the Study of the Liver (APASL) v2017 in the internal gadoxetic acid (EOB) validation set (75.5% vs. 77.2%, p = 0.044).

Conclusion

Two LI-RADS AFs (mild-moderate T2 hyperintensity and fat in mass) and AFP ≥ 200 ng/mL are useful for improving the sensitivity of Western and Eastern guidelines for HCCs ≤ 30 mm.

Key Points

Question The sensitivities of Western and Eastern guidelines for hepatocellular carcinoma ≤ 30 mm are still insufficient on extracellular contrast agent-enhanced MRI and gadoxetic acid-enhanced MRI.

Findings The use of the integrated “T2 + F/A” diagnostic criterion significantly improved the sensitivity of Western and Eastern guidelines for HCCs ≤ 30 mm on both ECA-MRI and EOB-MRI.

Clinical relevance Addressing a critical gap in noninvasive small HCC diagnosis protocols in Western and Eastern guidelines across multiple MRI contrast agents. By enabling more accurate MRI diagnosis of HCCs ≤ 30 mm, our findings could increase patients receiving curative treatments at the early stage, potentially improving outcomes.

Graphical Abstract